Insulin-inspired hippocampal neuron–targeting technology for protein drug delivery

Hippocampal neurons can be the first to be impaired with neurodegenerative disorders, including Alzheimer's disease (AD). Most drug candidates for causal therapy of AD cannot either enter the brain or accumulate around hippocampal neurons. Here, we genetically engineered insulin-fusion proteins, called hippocampal neuron-targeting (Ht) proteins, for targeting protein drugs to hippocampal neurons because insulin tends to accumulate in the neuronal cell layers of the hippocampus. In vitro examinations clarified that insulin and Ht proteins were internalized into the cultured hippocampal neurons through insulin receptor-mediated macropinocytosis. Cysteines were key determinants of the delivery of Ht proteins to hippocampal neurons, and insulin B chain mutant was most potent in delivering cargo proteins. In vivo accumulation of Ht proteins to hippocampal neuronal layers occurred after intracerebroventricular administration. Thus, hippocampal neuron-targeting technology can provide great help for developing protein drugs against neurodegenerative disorders.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2024-09-30
DOI
https://doi.org/10.1073/pnas.2407936121
Citations
11
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
2.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Insulin-inspired hippocampal neuron–targeting technology for protein drug delivery

Noriyasu Kamei, Mariko Takeda‐Morishita, Mana Yamada, Ryusei Shirata et al.
11 citations
Proceedings of the National Academy of Sciences
RNA Interference and Gene Delivery
2.57
article

Insulin-inspired hippocampal neuron–targeting technology for protein drug delivery

Noriyasu Kamei, Mariko Takeda‐Morishita, Mana Yamada, Ryusei Shirata, K. Ikeda, Yuki Miyauchi, M Mäki, Mika Miyata, Nanaka Nishiyama, S Fujisaki, Y Ohigashi, Yuka Ohmoto
article en
11 citations

Abstract

Hippocampal neurons can be the first to be impaired with neurodegenerative disorders, including Alzheimer's disease (AD). Most drug candidates for causal therapy of AD cannot either enter the brain or accumulate around hippocampal neurons. Here, we genetically engineered insulin-fusion proteins, called hippocampal neuron-targeting (Ht) proteins, for targeting protein drugs to hippocampal neurons because insulin tends to accumulate in the neuronal cell layers of the hippocampus. In vitro examinations clarified that insulin and Ht proteins were internalized into the cultured hippocampal neurons through insulin receptor-mediated macropinocytosis. Cysteines were key determinants of the delivery of Ht proteins to hippocampal neurons, and insulin B chain mutant was most potent in delivering cargo proteins. In vivo accumulation of Ht proteins to hippocampal neuronal layers occurred after intracerebroventricular administration. Thus, hippocampal neuron-targeting technology can provide great help for developing protein drugs against neurodegenerative disorders.

Proceedings of the National Academy of SciencesVol. 121(41)
Kobe Gakuin University (JP)
Takeda Science Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Japan Society for the Promotion of Science
Openalex Percentile: Top 10%
RNA Interference and Gene Delivery
2.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.